secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062936
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials
--------------------------------------------------------------------------------

- Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).
- Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.
- Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).
- CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.
- Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/0000950170-23-062936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/sprb-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer